ODAC Votes No on Genasense Accelerated Approval for CLL

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 10
Volume 15
Issue 10

The Oncologic Drugs Advisory Committee voted 7-to-3 against recommending accelerated approval for Genasense (oblimersen sodium, Genta) to treat relapsed/refractory chronic lymphocytic leukemia (CLL) in combination with fludarabine (Fludara) and cyclophosphamide.

SILVER SPRING, Maryland—The Oncologic Drugs Advisory Committee voted 7-to-3 against recommending accelerated approval for Genasense (oblimersen sodium, Genta) to treat relapsed/refractory chronic lymphocytic leukemia (CLL) in combination with fludarabine (Fludara) and cyclophosphamide.

Genasense increases the activity of chemotherapy drugs by stimulating apoptosis through downregulation of Bcl-2. Genta presented data from a pivotal, randomized phase III trial in 241 relapsed/refractory CLL patients, with response rate as its primary endpoint. Patients received fludarabine/cyclophosphamide with or without Genasense.

The study showed a significant difference in major response rates (complete response plus nodular partial response) between the Genasense arm and the control group (17% vs 7%), and a significantly more durable response (median 22 months for controls vs not reached at an estimated 3 years for Genasense). The company argued that response rate could serve as a surrogate for clinical benefit.

FDA's medical review team, however, argued that the trial did not meet the standard for accelerated approval, which requires "substantial evidence of safety and efficacy demonstrated in adequate and well-controlled trials (plurality indicating multiple trials)." Nor did it find that the results indicated that Genasense was "reasonably likely" to predict a clinical benefit in CLL patients. The drug did not improve overall response rate (CR/nPR/PR), time to progression, overall survival, or symptoms, compared with controls, and had added toxicity.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Related Content